RT Journal Article
SR Electronic
T1 Myositis associated anti-NT5C1A autoantibody in clinical practice
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.25.20043760
DO 10.1101/2020.03.25.20043760
A1 Ikenaga, Chiseko
A1 Findlay, Andrew R.
A1 Goyal, Namita A.
A1 Robinson, Sarah
A1 Cauchi, Jonathan
A1 Hussain, Yessar
A1 Wang, Leo H.
A1 Kershen, Joshua C.
A1 Beson, Brent A.
A1 Wallendorf, Michael
A1 Bucelli, Robert C.
A1 Mozaffar, Tahseen
A1 Pestronk, Alan
A1 Weihl, Conrad C.
YR 2020
UL http://medrxiv.org/content/early/2020/04/05/2020.03.25.20043760.abstract
AB Objective To define the diagnostic utility and clinicopathologic features correlating with anti-cytosolic 5′-nucleotidase 1A (NT5C1A) antibody positivity in idiopathic inflammatory myopathies (IIMs).Methods 4987 patients had anti-NT5C1A status clinically tested between 2014 and 2019 in the Washington University neuromuscular clinical laboratory. Using clinicopathologic information available for 630 of these patients, we classified them as inclusion body myositis (IBM), dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy (IMNM), non-specific myositis, or non-inflammatory muscle diseases.Results Anti-NT5C1A was found in 182/287 patients with IBM (63%), 11/53 patients with dermatomyositis (21%), 7/27 patients with antisynthetase syndrome (26%), 9/76 patients with IMNM (12%), 20/84 patients with non-specific myositis (24%), and 6/103 patients with non-inflammatory muscle diseases (6%). The sensitivity and specificity of anti-NT5C1A seropositivity for the diagnosis of IBM was 63% and 85%, respectively. Anti-NT5C1A positive IBM patients had a higher frequency of finger flexion weakness (p<0.01) and their biopsies harbored more COX negative fibers (p=0.04). 18% of anti-NT5C1A negative IBM patients seroconverted to anti-NT5C1A positive on repeat testing.Conclusions This is the largest description of patients tested by a clinical diagnostic lab for anti-NT5C1A. We confirm the sensitivity and specificity of anti-NT5C1A for IBM and identified clinicopathologic features in IBM which correlate with anti-NT5C1A status. Notably, anti-NT5C1A testing increased both the diagnostic sensitivity and specificity of IBM when combined with patient age, gender and creatine kinase (CK) level. We propose that future IBM diagnostic criteria include anti-NT5C1A testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by CureIBM, Catalyze a Cure and NIH grants K24AR073317 to CCW and K08AR075894 to ARF.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request.